Ong VH - Search Results

1

Targeted therapies for systemic sclerosis.

Denton CP, Ong VH. Denton CP, et al. Among authors: ong vh. Nat Rev Rheumatol. 2013 Aug;9(8):451-64. doi: 10.1038/nrrheum.2013.46. Epub 2013 Apr 9. Nat Rev Rheumatol. 2013. PMID: 23567456 Review.

2

Monocyte chemoattractant protein 3 as a mediator of fibrosis: Overexpression in systemic sclerosis and the type 1 tight-skin mouse.

Ong VH, Evans LA, Shiwen X, Fisher IB, Rajkumar V, Abraham DJ, Black CM, Denton CP. Ong VH, et al. Arthritis Rheum. 2003 Jul;48(7):1979-91. doi: 10.1002/art.11164. Arthritis Rheum. 2003. PMID: 12847692

3

The myth of pulmonary Raynaud's phenomenon: the contribution of pulmonary arterial vasospasm in patients with systemic sclerosis related pulmonary arterial hypertension.

Mukerjee D, Yap LB, Ong V, Denton CP, Howells K, Black CM, Coghlan JG. Mukerjee D, et al. Ann Rheum Dis. 2004 Dec;63(12):1627-31. doi: 10.1136/ard.2003.015289. Ann Rheum Dis. 2004. PMID: 15547087 Free PMC article.

4

Management of systemic sclerosis.

Ong VH, Brough G, Denton CP. Ong VH, et al. Clin Med (Lond). 2005 May-Jun;5(3):214-9. doi: 10.7861/clinmedicine.5-3-214. Clin Med (Lond). 2005. PMID: 16011210 Free PMC article. Review. No abstract available.

5

Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation.

Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, Denton CP. Carulli MT, et al. Among authors: ong vh. Arthritis Rheum. 2005 Dec;52(12):3772-82. doi: 10.1002/art.21396. Arthritis Rheum. 2005. PMID: 16320328

6

Innovative therapies for systemic sclerosis.

Ong VH, Denton CP. Ong VH, et al. Curr Opin Rheumatol. 2010 May;22(3):264-72. doi: 10.1097/BOR.0b013e328337c3d6. Curr Opin Rheumatol. 2010. PMID: 20190640 Review.

7

Clinical and serological hallmarks of systemic sclerosis overlap syndromes.

Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP. Pakozdi A, et al. Among authors: ong vh. J Rheumatol. 2011 Nov;38(11):2406-9. doi: 10.3899/jrheum.101248. Epub 2011 Aug 15. J Rheumatol. 2011. PMID: 21844148

8

Clinical and pathological significance of interleukin 6 overexpression in systemic sclerosis.

Khan K, Xu S, Nihtyanova S, Derrett-Smith E, Abraham D, Denton CP, Ong VH. Khan K, et al. Among authors: ong vh. Ann Rheum Dis. 2012 Jul;71(7):1235-42. doi: 10.1136/annrheumdis-2011-200955. Epub 2012 May 14. Ann Rheum Dis. 2012. PMID: 22586157

9

Impact of hallmark autoantibody reactivity on early diagnosis in scleroderma.

Moinzadeh P, Nihtyanova SI, Howell K, Ong VH, Denton CP. Moinzadeh P, et al. Among authors: ong vh. Clin Rev Allergy Immunol. 2012 Dec;43(3):249-55. doi: 10.1007/s12016-012-8331-1. Clin Rev Allergy Immunol. 2012. PMID: 22711501 Review.

10

Serum interleukin 6 is predictive of early functional decline and mortality in interstitial lung disease associated with systemic sclerosis.

De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, Zappala CJ, Visca D, Maher TM, Denton CP, Ong VH, Abraham DJ, Kelleher P, Hector L, Wells AU, Renzoni EA. De Lauretis A, et al. Among authors: ong vh. J Rheumatol. 2013 Apr;40(4):435-46. doi: 10.3899/jrheum.120725. Epub 2013 Feb 1. J Rheumatol. 2013. PMID: 23378460

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results